Teva Pharmaceutical Industries Income from Continuous Operations 2010-2024 | TEVA
Teva Pharmaceutical Industries annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Teva Pharmaceutical Industries income from continuous operations for the quarter ending June 30, 2024 was $-0.874B, a 3.53% decline year-over-year.
- Teva Pharmaceutical Industries income from continuous operations for the twelve months ending June 30, 2024 was $-0.749B, a 69.38% decline year-over-year.
- Teva Pharmaceutical Industries annual income from continuous operations for 2023 was $-0.615B, a 75.39% decline from 2022.
- Teva Pharmaceutical Industries annual income from continuous operations for 2022 was $-2.499B, a 648.03% decline from 2021.
- Teva Pharmaceutical Industries annual income from continuous operations for 2021 was $0.456B, a 111.12% decline from 2020.
Teva Pharmaceutical Industries Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-615 |
| 2022 |
$-2,499 |
| 2021 |
$456 |
| 2020 |
$-4,100 |
| 2019 |
$-1,000 |
| 2018 |
$-2,472 |
| 2017 |
$-16,449 |
| 2016 |
$311 |
| 2015 |
$1,597 |
| 2014 |
$3,042 |
| 2013 |
$1,253 |
| 2012 |
$1,910 |
| 2011 |
$2,768 |
| 2010 |
$3,339 |
| 2009 |
$2,004 |
Teva Pharmaceutical Industries Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$-874 |
| 2024-03-31 |
$-419 |
| 2023-12-31 |
$457 |
| 2023-09-30 |
$87 |
| 2023-06-30 |
$-906 |
| 2023-03-31 |
$-253 |
| 2022-12-31 |
$-1,347 |
| 2022-09-30 |
$60 |
| 2022-06-30 |
$-260 |
| 2022-03-31 |
$-952 |
| 2021-12-31 |
$-151 |
| 2021-09-30 |
$301 |
| 2021-06-30 |
$221 |
| 2021-03-31 |
$85 |
| 2020-12-31 |
$161 |
| 2020-09-30 |
$-4,339 |
| 2020-06-30 |
$53 |
| 2020-03-31 |
$25 |
| 2019-12-31 |
$75 |
| 2019-09-30 |
$-307 |
| 2019-06-30 |
$-671 |
| 2019-03-31 |
$-97 |
| 2018-12-31 |
$-3,243 |
| 2018-09-30 |
$-197 |
| 2018-06-30 |
$-166 |
| 2018-03-31 |
$1,134 |
| 2017-12-31 |
$-11,730 |
| 2017-09-30 |
$610 |
| 2017-06-30 |
$-5,970 |
| 2017-03-31 |
$641 |
| 2016-12-31 |
$-974 |
| 2016-09-30 |
$410 |
| 2016-06-30 |
$242 |
| 2016-03-31 |
$633 |
| 2015-12-31 |
$498 |
| 2015-09-30 |
$116 |
| 2015-06-30 |
$539 |
| 2015-03-31 |
$444 |
| 2014-12-31 |
$694 |
| 2014-09-30 |
$863 |
| 2014-06-30 |
$745 |
| 2014-03-31 |
$740 |
| 2013-12-31 |
$377 |
| 2013-09-30 |
$706 |
| 2013-06-30 |
$-456 |
| 2013-03-31 |
$626 |
| 2012-12-31 |
$280 |
| 2012-09-30 |
$-84 |
| 2012-06-30 |
$859 |
| 2012-03-31 |
$855 |
| 2011-12-31 |
$505 |
| 2011-09-30 |
$918 |
| 2011-06-30 |
$580 |
| 2011-03-31 |
$765 |
| 2010-12-31 |
$771 |
| 2010-09-30 |
$1,052 |
| 2010-06-30 |
$800 |
| 2010-03-31 |
$714 |
| 2009-12-31 |
$379 |
| 2009-09-30 |
$649 |
| 2009-06-30 |
$521 |
| 2009-03-31 |
$451 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$20.120B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
